부산대학교 도서관

Background: Specific components of lipid profile seem to differently impact on immune activity against cancer and unraveling their prognostic role in patients with solid cancer treated with immune checkpoint inhibitors (ICIs) is needed. Materials and Methods: We retrospectively collected baseline clinicopathological characteristics including circulating lipid profile (total cholesterol [TC], triglycerides [TG], low-density lipoproteins [LDL], high-density lipoproteins [HDL]) of patients with consecutive solid cancer treated with ICIs, and we investigated their role in predicting clinical outcomes. Results: At a median follow-up of 32.9 months, among 430 enrolled patients, those with TC [greater than or equal to] 200 mg/dl showed longer median progression-free survival (mPFS; 6.6 vs. 4.7 months, P = .4), although not reaching statistical significance, and significantly longer median overall survival (mOS; 19.4 vs. 10.8 months, P = .02) compared to those with TC < 200 mg/dl. Conversely, patients with TG [greater than or equal to]150 mg/dl displayed shorter PFS (3.4 vs. 5.1 months, P = .02) and OS (71 vs. 12.9 months, P = .009) compared to those with TG Conclusions: We developed a lipid score that defined subgroups of patients with cancer who differently benefit from ICIs. Further mechanistic insights are warranted to clarify the prognostic and predictive role of lipid profile components in patients treated with ICIs. Key words: lipid metabolism; immune checkpoint inhibitors; lipid profile; triglycerides-high-density lipoproteins ratio
Implications for Practice In patients with advanced solid tumors treated with immune checkpoint inhibitors, combining total cholesterol with triglycerides in a "lipid score" allowed us to define three subgroups of [...]